Equities research analysts expect Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) to announce earnings per share (EPS) of ($0.47) for the current quarter, Zacks reports. Six analysts have made estimates for Denali Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.66) and the highest estimate coming in at $0.04. Denali Therapeutics posted earnings per share of ($0.58) during the same quarter last year, which suggests a positive year over year growth rate of 19%. The business is scheduled to announce its next earnings results on Monday, January 1st.
On average, analysts expect that Denali Therapeutics will report full-year earnings of ($2.60) per share for the current fiscal year, with EPS estimates ranging from ($2.84) to ($2.15). For the next year, analysts anticipate that the business will post earnings of ($2.46) per share, with EPS estimates ranging from ($3.07) to ($1.03). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI – Get Rating) last issued its quarterly earnings results on Monday, February 28th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.21). The business had revenue of $12.51 million during the quarter, compared to the consensus estimate of $38.16 million. Denali Therapeutics had a negative return on equity of 27.99% and a negative net margin of 597.15%.
Several research analysts recently issued reports on DNLI shares. The Goldman Sachs Group decreased their price target on shares of Denali Therapeutics from $114.00 to $98.00 and set a “buy” rating for the company in a research note on Monday, March 7th. Morgan Stanley reduced their price target on shares of Denali Therapeutics from $99.00 to $91.00 and set an “overweight” rating for the company in a research note on Thursday, January 6th. TheStreet lowered shares of Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Wednesday, March 2nd. Finally, Wedbush reiterated an “outperform” rating on shares of Denali Therapeutics in a research note on Tuesday, March 1st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $85.88.
Shares of Denali Therapeutics stock traded down $0.93 during trading on Friday, hitting $30.11. The company’s stock had a trading volume of 351,897 shares, compared to its average volume of 463,517. The company has a fifty day simple moving average of $32.75 and a two-hundred day simple moving average of $40.38. The company has a market capitalization of $3.70 billion, a PE ratio of -12.60 and a beta of 1.82. Denali Therapeutics has a 52 week low of $28.76 and a 52 week high of $79.70.
In related news, Director Marc Tessier-Lavigne sold 20,000 shares of the stock in a transaction that occurred on Wednesday, March 23rd. The shares were sold at an average price of $33.83, for a total value of $676,600.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Carole Ho sold 2,918 shares of the stock in a transaction that occurred on Friday, February 11th. The stock was sold at an average price of $34.71, for a total transaction of $101,283.78. The disclosure for this sale can be found here. Insiders have sold 43,210 shares of company stock worth $1,496,386 in the last quarter. Company insiders own 17.00% of the company’s stock.
Large investors have recently modified their holdings of the stock. Baillie Gifford & Co. grew its stake in shares of Denali Therapeutics by 0.3% during the 4th quarter. Baillie Gifford & Co. now owns 15,056,381 shares of the company’s stock worth $671,515,000 after purchasing an additional 46,565 shares during the period. BlackRock Inc. grew its stake in shares of Denali Therapeutics by 7.3% during the 4th quarter. BlackRock Inc. now owns 8,110,822 shares of the company’s stock worth $361,741,000 after purchasing an additional 549,985 shares during the period. Temasek Holdings Private Ltd grew its stake in shares of Denali Therapeutics by 21.7% during the 3rd quarter. Temasek Holdings Private Ltd now owns 5,369,487 shares of the company’s stock worth $270,891,000 after purchasing an additional 959,030 shares during the period. State Street Corp grew its stake in shares of Denali Therapeutics by 8.2% during the 4th quarter. State Street Corp now owns 3,027,571 shares of the company’s stock worth $135,030,000 after purchasing an additional 229,437 shares during the period. Finally, Credit Suisse AG grew its stake in Denali Therapeutics by 0.8% in the 3rd quarter. Credit Suisse AG now owns 1,982,473 shares of the company’s stock valued at $100,015,000 after acquiring an additional 15,965 shares during the period. Institutional investors own 69.15% of the company’s stock.
Denali Therapeutics Company Profile (Get Rating)
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Denali Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.